The effect of oral supplementation of zinc on glycemic status, lipid profile and body composition in non-diabetic hemodialysis patients

Phase 3

Conditions: non-diabetic hemodialysis patients.
Chronic kidney disease, stage 5
N18.5

Registration Number: IRCT20191223045862N1

Lead Sponsor: Oroumia University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 66

Inclusion Criteria

At least 6 months have passed since the start of hemodialysis.
Patients undergo hemodialysis 3 times a week for 4-3 hours.
Non-diabetic hemodialysis patients

Exclusion Criteria

Patients are candidates for kidney transplant.
Patients with any symptoms of gastrointestinal disorders.
Patients taking penicillamine medication.
Patients taking glucocorticoid medication.
Patients taking estrogen medication.
Patients taking the antibiotic medication.
Women taking oral contraceptives.
Patients taking lipid lowering medications.
Patients with zinc malabsorption (Acroderma enteropathica).
Pregnant and lactating women.

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serum zinc level. Timepoint: At the beginning (day 0) and end of the intervention (day 60). Method of measurement: Serum zinc level was measured using Dialab kit by BT-1500 autoanalyzer in micrograms / dL.;Insulin resistance. Timepoint: At the beginning (day 0) and end of the intervention (day 60). Method of measurement: Insulin resistance was calculated using the homeostasis model formula (HOMA-IR) as follows. HOMA-IR = [fasting insulin (µU/L) × fasting blood glucose (mg/dl)]/405.

Secondary Outcome Measures